A nasal-drop RSV vaccine worked best in babies who'd never met the virus

Respiratory syncytial virus is the leading cause of serious lower-respiratory illness in babies, and the protection now reaching them — the long-acting antibody nirsevimab and a vaccine given to mothers in pregnancy — works by handing infants ready-made antibodies rather than teaching their own immune systems. A different strategy would be an active vaccine the baby responds to directly. A phase 1/2 trial published in The Lancet Microbe on October 13 tests one such candidate and shows why a baby's prior exposure to the virus changes everything [s1].

What the trial did

The vaccine, RSVt, is live-attenuated — a weakened form of RSV given as nasal drops, designed to mimic a mild natural infection and prime the airway's own defences [s1]. The trial recruited healthy children aged 6 to 18 months at sites in the USA, Chile and Honduras, assigning them to low-dose or high-dose RSVt, given once or twice, or to placebo [s1]. The analysis reported here centres on cohort 4, the primary comparison group, in which 180 infants were randomly assigned to low-dose RSVt (61), high-dose RSVt (58) or placebo (61), with a mean age of about 10.5 months [s1][s2].

Crucially, the researchers split the children by baseline serostatus — whether blood tests showed they had already encountered RSV [s1]. The main outcomes were immunogenicity, measured as a four-fold or greater rise in RSV-neutralising antibodies by day 84, and vaccine-virus shedding, measured by PCR [s1]. The trial was funded by Sanofi [s1].

What it found

Among infants who were RSV-naive — no prior exposure — the vaccine clearly took [s1]. By day 84, a four-fold or greater rise in neutralising antibodies appeared in 19 of 28 (67.9%) low-dose recipients and 13 of 21 (61.9%) high-dose recipients, against just 2 of 27 (7.4%) on placebo [s1]. The response was strongest in the subset who were fully seronegative, with no maternal antibody left: there, high-dose RSVt produced a four-fold rise in 10 of 11 children (90.9%), and the low dose in 15 of 20 (75.0%) [s1].

Among children who had already met RSV, the picture inverted. Four-fold rises were seen in only 2 of 14 (14.3%) low-dose and 1 of 20 (5.0%) high-dose recipients — no better than the 13.0% on placebo [s1]. Shedding of the vaccine virus, a sign that it was replicating and priming the immune system, was common in RSV-naive infants — roughly half shed detectable virus by day 7 — and absent in placebo recipients [s1]. No vaccine-related serious adverse events were reported [s1].

How much weight the numbers carry

This is an early-stage immunogenicity trial, not an efficacy trial, so it measures antibody responses and viral replication — not whether vaccinated babies caught fewer or milder RSV infections. The numbers per subgroup are small; a response rate built on 11 or 20 children carries wide uncertainty, and the study was analysed descriptively rather than powered to prove a difference. Read it as a signal about how the vaccine behaves, not as a verdict on whether it protects.

The serostatus split is the finding that will shape what comes next. A live vaccine that replicates in the nose has little room to work if the child's airway is already primed from a real infection, which is why the response all but vanished in RSV-experienced infants. That points to a narrow target window — the youngest, truly naive babies — and to the practical problem of identifying them. The authors also flag a subtler caution: serum antibody responses and viral shedding did not line up neatly, which suggests blood-antibody measures alone may not capture everything a nasal vaccine does to airway immunity.

Why it matters

The infants most endangered by RSV are the youngest, and they are exactly the group in whom passive antibody and this active nasal vaccine could in principle be complementary. Showing that RSVt reliably primes truly naive babies — while confirming it does little in those already exposed — is the kind of result that tells developers who a live intranasal vaccine is, and is not, for.

What to watch

Whether larger trials can turn these antibody signals into measured protection against RSV illness; how a live nasal vaccine would fit alongside maternal vaccination and nirsevimab rather than compete with them; and whether the mismatch between serum antibodies and local airway immunity means future trials need better mucosal measures.

This article describes an early-phase clinical trial and is informational only. It is not medical advice.